that local interleukin-2 (IL-2) therapy in combination with radiotherapy is an effective treatment for late-stage nasopharyngeal carcinoma (NPC). The authors conclude that radiotherapy combined ...

"Our proposed approach involves treating patients who are at high risk of developing rheumatic fever, with a five-day course ...

Lymphir is a recombinant fusion protein that combines an IL-2 binding domain with diphtheria ... lymphoma – after at least one prior systemic therapy. It is a reformulated and purified form ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

San Francisco, US Tuesday, April 1, 2025, 15:00 Hrs [IST] ...

Despite the challenges, there's still plenty of interest in IL-2 as a cancer therapy, with several companies, including Medicenna, Anaveon, Cue Biopharma, Aulos Bioscience, and Synthekine in ...

which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

IBI363 has demonstrated outstanding efficacy signals in immunotherapy (IO)-naïve melanoma patients across two earlier clinical trials (Phase 1a/ 1b study NCT05460767 and Phase 2 study NCT06081920), ...

Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from ...

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced ...